MENU
OCT 22, 2020

OncomineWorld Autumn: A virtual NGS education meeting


OncomineWorld Autumn is an all-new opportunity to learn about the latest developments in cancer genomic profiling. Access all OncomineWorld content from the Spring and Autumn events in one place - This virtual NGS education meeting is free and on demand!

What’s new to OncomineWorld Autumn?

  • New presentations added to our program of 27 on-demand talks - Listen to presentations in the "Oncology biomarkers testing education track" or hear new Genexus System users share their experiences, and much more!
  • Demonstrations of the Ion Torrent Genexus System, recorded from a Thermo Fisher Scientific lab
  • See the latest NGS research from Thermo Fisher Scientific with 11 new posters in the Poster Hall
  • New content in the Precision Oncology Hall, with all about why and how genomic profiling for precision oncology should be done in-house, locally and close to patients

In this virtual NGS education meeting you will be able to:

  • Earn CE credits from on-demand or live presentations from leading NGS users on topics such as comprehensive genomic profiling (CGP), the future of precision oncology biomarkers testing, personal experiences with different NGS products and solutions, and much more.
  • Explore our virtual laboratories to learn about the new world of easy and fast NGS – the Genexus System - and many NGS application areas, including emerging NSCLC biomarkers, liquid biopsy, and hemato- oncology research.
  • Visit the Precision Oncology Hall to access videos, posters, and more on the future potential of NGS to enable access to precision medicine for more patients
  • See the latest NGS research from Thermo Fisher Scientific with 11 new posters in the Poster Hall

Sincerely,

Your Thermo Fisher Scientific Oncology NGS team

 

For Research Use Only. Not for use in diagnostic procedures.


Speakers

Show Resources
Agenda
  • LIVE DEMO: The Ion Torrent Genexus System
    OCT 22, 2020 2:10 PM PDT
    LIVE DEMO: The Ion Torrent Genexus System
    Andrew Hutchison
    Associate Director of Product Management, Clinical Sequencing Division, Thermo Fisher Scientific
  • Evaluation of the Oncomine Comprehensive Assay Plus for Profiling of Solid Tumours
    OCT 22, 2020 1:35 PM PDT
    Evaluation of the Oncomine Comprehensive Assay Plus for Profiling of Solid Tumours
    Jane Bayani, PhD
    Principal Research Scientist, Ontario Institute for Cancer Research
  • Utilizing the Genexus System to Detect Complex Genetic Variants in Human Tissue Specimens
    OCT 22, 2020 1:15 PM PDT
    Utilizing the Genexus System to Detect Complex Genetic Variants in Human Tissue Specimens
    Craig Mackinnon, MD, PhD
    Director, Genomic Diagnostics and Bioinformatics - Professor, Department of Pathology, University of Alabama at Birmingham
  • Clinical impact of Next-Generation Sequencing (NGS) Testing: A hematopathologist's perspective
    OCT 22, 2020 12:25 PM PDT
    Clinical impact of Next-Generation Sequencing (NGS) Testing: A hematopathologist's perspective
    Megan S. Lim, MD, PhD
    Director of the Division of Hematopathology, Hospital of the University of Pennsylvania
  • Molecular Testing of NSCLC Biopsies: Making mountains out of molehills
    OCT 22, 2020 12:05 PM PDT
    Molecular Testing of NSCLC Biopsies: Making mountains out of molehills
    Carmen Kletecka, MD, FCAP, FASCP
    Medical Director, Molecular Oncology Diagnostics Laboratory - U.S. Department of Veterans Affairs
  • LIVE DEMO: The Ion Torrent Genexus System
    OCT 22, 2020 5:15 PM CEST
    LIVE DEMO: The Ion Torrent Genexus System
    Andrew Hutchison
    Associate Director of Product Management, Clinical Sequencing Division, Thermo Fisher Scientific
  • First Experiences with Oncomine™ Comprehensive Assay Plus for comprehensive genomic profiling
    OCT 22, 2020 4:40 PM CEST
    First Experiences with Oncomine™ Comprehensive Assay Plus for comprehensive genomic profiling
    Ines Raineri, MD
    Staff Pathologist, Institute for Pathology medica AG
  • NGS evolution in Solid Tumours, from S5-XL to Genexus
    OCT 22, 2020 4:20 PM CEST
    NGS evolution in Solid Tumours, from S5-XL to Genexus
    Javier Hernandez-Losa, PhD
    Director of Molecular Biology Laboratory, Department of Pathology - Vall d´Hebron Hospital
  • Next Generation rEvolution in Myeloid Neoplasms clinical research
    OCT 22, 2020 3:35 PM CEST
    Next Generation rEvolution in Myeloid Neoplasms clinical research
    Giada Rotunno, PhD
    Research Scientist, University of Florence
  • NGS for precision oncology in solid tumors: from research to clinical practice
    OCT 22, 2020 3:05 PM CEST
    NGS for precision oncology in solid tumors: from research to clinical practice
    Nicola Normanno, MD
    Director of the Cell Biology and Biotherapy Unit and Translational Research Department, National Cancer Institute Fondazione G. Pascale, Naples
  • LIVE DEMO: The Ion Torrent Genexus System
    OCT 22, 2020 2:10 PM SGT
    LIVE DEMO: The Ion Torrent Genexus System
    Andrew Hutchison
    Associate Director of Product Management, Clinical Sequencing Division, Thermo Fisher Scientific
  • Latest Developments with the Genexus System
    OCT 22, 2020 1:35 PM SGT
    Latest Developments with the Genexus System
    Dr. Jose Luis Costa
    Medical Director, Thermo Fisher Scientific
  • OCA Plus DNA evaluation for comprehensive genomic profiling in clinical research
    OCT 22, 2020 1:15 PM SGT
    OCA Plus DNA evaluation for comprehensive genomic profiling in clinical research
    Ahwon Lee, MD, PhD
    Professor, Catholic University of Korea and Pathologist, Seoul St. Mary's Hospital
  • The role of PARPis and HRD testing in advanced ovarian cancer
    OCT 22, 2020 12:25 PM SGT
    The role of PARPis and HRD testing in advanced ovarian cancer
    Natalie Ngoi, MBBS, MMed, MRCP
    Associate Consultant, National University Cancer Institute, Singapore
  • Incorporating NGS in an Asian non-small cell lung cancer (NSCLC) population - a cost-effectiveness analysis
    OCT 22, 2020 12:05 PM SGT
    Incorporating NGS in an Asian non-small cell lung cancer (NSCLC) population - a cost-effectiveness analysis
    Aaron Tan, PhD
    Oncology Fellow, Resident Physician, National Cancer Centre, Singapore
  • Haemato-Oncology Applications of BCR Immune Repertoire Sequencing
    MAY 14, 2020 7:05 PM EDT
    Haemato-Oncology Applications of BCR Immune Repertoire Sequencing
    Timothy Looney, PhD
    Associate Director, Bioinformatics; Clinical Next-Generation Sequencing
  • Genomic profiling of prostate cancer cells from urine using Oncomine Pan Cancer Cell Free Assay
    MAY 14, 2020 6:40 PM EDT
    Genomic profiling of prostate cancer cells from urine using Oncomine Pan Cancer Cell Free Assay
    Jane Bayani, PhD
    Principal Research Scientist, Ontario Institute for Cancer Research
  • Experience with Oncomine Myeloid Research Assay
    MAY 14, 2020 6:05 PM EDT
    Experience with Oncomine Myeloid Research Assay
    Xia Li, PhD, FACMG, DABMGG
    Scientific Medical Director, Sonora Quest Laboratories, Tempe, US
  • First experience with the Ion Torrent Genexus Workflow
    MAY 14, 2020 5:40 PM EDT
    First experience with the Ion Torrent Genexus Workflow
    Kojo Elenitoba-Johnson, MD
    Director, Center for Personalized Diagnostics Director, Division of Precision and Computational Diagnostics, University of Pennsylvania Perelman School of Medicine
  • Molecular Profiling for Treatment Guidance of Hematologic Malignancies by Next Generation Sequencing
    MAY 14, 2020 5:00 PM EDT
    Molecular Profiling for Treatment Guidance of Hematologic Malignancies by Next Generation Sequencing
    Xia Li, PhD, FACMG, DABMGG
    Scientific Medical Director, Sonora Quest Laboratories, Tempe, US
  • Lymphoid and Myeloid NGS Molecular Characterization - Assessing the Journey to Answers
    MAY 14, 2020 4:40 PM CEST
    Lymphoid and Myeloid NGS Molecular Characterization - Assessing the Journey to Answers
    Marianne Grantham
    Clinical Scientist, Head of Cytogenetics and Molecular Haematology, Barts Health NHS Trust The Royal London Hospital
  • Advantages and Challenges of Broad Molecular Profiling
    MAY 14, 2020 4:15 PM CEST
    Advantages and Challenges of Broad Molecular Profiling
    Ilaria Alborelli, PhD
    Scientific Operations Manager, Molecular Assay Development Unit Institute of Medical Genetics and Pathology, University Hospital of Basel - Switzerland
  • Genexus - A Major Step Forward in Diagnostic NGS
    MAY 14, 2020 3:30 PM CEST
    Genexus - A Major Step Forward in Diagnostic NGS
    Michael Hummel, PhD
    Head of Molecular Pathology, Charité - Universitätsmedizin Berlin, Institute of Pathology, Germany
  • MAY 14, 2020 3:00 PM CEST
    Analysis of Solid Tumor Genomic Landscape in Liquid Biopsy
    Nicola Normanno, MD
    Director of the Cell Biology and Biotherapy Unit and Translational Research Department, National Cancer Institute Fondazione G. Pascale, Naples
  • Emerging Biomarkers in Non-small Cell Lung Cancer
    MAY 14, 2020 3:00 PM CEST
    Emerging Biomarkers in Non-small Cell Lung Cancer
    Luca Quagliata, PhD
    Global Head of Medical Affairs, Clinical NGS and Oncology Division, Thermo Fisher Scientific
    Continuing Education: Florida CE | P.A.C.E. CE
  • Oncomine Precision Assay on Ion Torrent Genexus System for liquid biopsy sample
    MAY 14, 2020 2:40 PM SGT
    Oncomine Precision Assay on Ion Torrent Genexus System for liquid biopsy sample
    Siew-Kee (Amanda) Low, PhD
    Group Leader for Cancer Neoantigen Vaccine Development Group, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research (JFCR)
  • First Experience from New World of Easy NGS - Ion Torrent Genexus Workflow
    MAY 14, 2020 2:15 PM SGT
    First Experience from New World of Easy NGS - Ion Torrent Genexus Workflow
    Philip Jermann, PhD
    Director of the Molecular Assay Development Unit, Institute of Pathology and Medical Genetics of Basel
  • NATA Accreditation of Next Generation Sequencing for CDx Testing
    MAY 14, 2020 1:25 PM SGT
    NATA Accreditation of Next Generation Sequencing for CDx Testing
    Luke Hesson, PhD, FFScRCPA
    Laboratory Director, KCCG Sequencing Facility & Cancer Diagnostics​, Australia
    Continuing Education: Florida CE | P.A.C.E. CE
  • Test Validation in Medical Laboratories: the Australian Perspective
    MAY 14, 2020 1:25 PM SGT
    Test Validation in Medical Laboratories: the Australian Perspective
    Luke Hesson, PhD, FFScRCPA
    Laboratory Director, KCCG Sequencing Facility & Cancer Diagnostics​, Australia
  • Implementation of Multigene Testing for 1st line NSCLC - A Malaysian initiative
    MAY 14, 2020 1:00 PM SGT
    Implementation of Multigene Testing for 1st line NSCLC - A Malaysian initiative
    Pathmanathan Rajadurai, MBBS, FRCPA, FRCPath
    Senior Consultant Pathologist and Laboratory Director
  • Live Session 1
    • Part 1: NGS in Precision Oncology - General Education
    • Implementation of Multigene Testing for 1st line NSCLC - A Malaysian initiative
      MAY 14, 2020 1:00 PM SGT
      Implementation of Multigene Testing for 1st line NSCLC - A Malaysian initiative
      Pathmanathan Rajadurai, MBBS, FRCPA, FRCPath
      Senior Consultant Pathologist and Laboratory Director
    • Test Validation in Medical Laboratories: the Australian Perspective
      MAY 14, 2020 1:25 PM SGT
      Test Validation in Medical Laboratories: the Australian Perspective
      Luke Hesson, PhD, FFScRCPA
      Laboratory Director, KCCG Sequencing Facility & Cancer Diagnostics​, Australia
    • NATA Accreditation of Next Generation Sequencing for CDx Testing
      MAY 14, 2020 1:25 PM SGT
      NATA Accreditation of Next Generation Sequencing for CDx Testing
      Luke Hesson, PhD, FFScRCPA
      Laboratory Director, KCCG Sequencing Facility & Cancer Diagnostics​, Australia
      Continuing Education: Florida CE | P.A.C.E. CE
    • Part 2: Experiences with Oncomine Solutions for Clinical Research
    • First Experience from New World of Easy NGS - Ion Torrent Genexus Workflow
      MAY 14, 2020 2:15 PM SGT
      First Experience from New World of Easy NGS - Ion Torrent Genexus Workflow
      Philip Jermann, PhD
      Director of the Molecular Assay Development Unit, Institute of Pathology and Medical Genetics of Basel
    • Oncomine Precision Assay on Ion Torrent Genexus System for liquid biopsy sample
      MAY 14, 2020 2:40 PM SGT
      Oncomine Precision Assay on Ion Torrent Genexus System for liquid biopsy sample
      Siew-Kee (Amanda) Low, PhD
      Group Leader for Cancer Neoantigen Vaccine Development Group, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research (JFCR)
  • Live Session 2
    • Part 1: NGS IN PRECISION ONCOLOGY - GENERAL EDUCATION
    • MAY 14, 2020 3:00 PM CEST
      Analysis of Solid Tumor Genomic Landscape in Liquid Biopsy
      Nicola Normanno, MD
      Director of the Cell Biology and Biotherapy Unit and Translational Research Department, National Cancer Institute Fondazione G. Pascale, Naples
    • Part 1: NGS in Precision Oncology - General Education
    • Emerging Biomarkers in Non-small Cell Lung Cancer
      MAY 14, 2020 3:00 PM CEST
      Emerging Biomarkers in Non-small Cell Lung Cancer
      Luca Quagliata, PhD
      Global Head of Medical Affairs, Clinical NGS and Oncology Division, Thermo Fisher Scientific
      Continuing Education: Florida CE | P.A.C.E. CE
    • Part 2: Experiences with Oncomine Solutions for Clinical Research
    • Genexus - A Major Step Forward in Diagnostic NGS
      MAY 14, 2020 3:30 PM CEST
      Genexus - A Major Step Forward in Diagnostic NGS
      Michael Hummel, PhD
      Head of Molecular Pathology, Charité - Universitätsmedizin Berlin, Institute of Pathology, Germany
    • Advantages and Challenges of Broad Molecular Profiling
      MAY 14, 2020 4:15 PM CEST
      Advantages and Challenges of Broad Molecular Profiling
      Ilaria Alborelli, PhD
      Scientific Operations Manager, Molecular Assay Development Unit Institute of Medical Genetics and Pathology, University Hospital of Basel - Switzerland
    • Lymphoid and Myeloid NGS Molecular Characterization - Assessing the Journey to Answers
      MAY 14, 2020 4:40 PM CEST
      Lymphoid and Myeloid NGS Molecular Characterization - Assessing the Journey to Answers
      Marianne Grantham
      Clinical Scientist, Head of Cytogenetics and Molecular Haematology, Barts Health NHS Trust The Royal London Hospital
  • Live Session 3
    • Part 1: NGS in Precision Oncology - General Education
    • Molecular Profiling for Treatment Guidance of Hematologic Malignancies by Next Generation Sequencing
      MAY 14, 2020 5:00 PM EDT
      Molecular Profiling for Treatment Guidance of Hematologic Malignancies by Next Generation Sequencing
      Xia Li, PhD, FACMG, DABMGG
      Scientific Medical Director, Sonora Quest Laboratories, Tempe, US
    • Part 2: Experiences with Oncomine Solutions for Clinical Research
    • First experience with the Ion Torrent Genexus Workflow
      MAY 14, 2020 5:40 PM EDT
      First experience with the Ion Torrent Genexus Workflow
      Kojo Elenitoba-Johnson, MD
      Director, Center for Personalized Diagnostics Director, Division of Precision and Computational Diagnostics, University of Pennsylvania Perelman School of Medicine
    • Experience with Oncomine Myeloid Research Assay
      MAY 14, 2020 6:05 PM EDT
      Experience with Oncomine Myeloid Research Assay
      Xia Li, PhD, FACMG, DABMGG
      Scientific Medical Director, Sonora Quest Laboratories, Tempe, US
    • Genomic profiling of prostate cancer cells from urine using Oncomine Pan Cancer Cell Free Assay
      MAY 14, 2020 6:40 PM EDT
      Genomic profiling of prostate cancer cells from urine using Oncomine Pan Cancer Cell Free Assay
      Jane Bayani, PhD
      Principal Research Scientist, Ontario Institute for Cancer Research
    • Haemato-Oncology Applications of BCR Immune Repertoire Sequencing
      MAY 14, 2020 7:05 PM EDT
      Haemato-Oncology Applications of BCR Immune Repertoire Sequencing
      Timothy Looney, PhD
      Associate Director, Bioinformatics; Clinical Next-Generation Sequencing
  • Asia Pacific Session 1
    • Part 1: NGS in precision oncology - general education
    • Incorporating NGS in an Asian non-small cell lung cancer (NSCLC) population - a cost-effectiveness analysis
      OCT 22, 2020 12:05 PM SGT
      Incorporating NGS in an Asian non-small cell lung cancer (NSCLC) population - a cost-effectiveness analysis
      Aaron Tan, PhD
      Oncology Fellow, Resident Physician, National Cancer Centre, Singapore
    • The role of PARPis and HRD testing in advanced ovarian cancer
      OCT 22, 2020 12:25 PM SGT
      The role of PARPis and HRD testing in advanced ovarian cancer
      Natalie Ngoi, MBBS, MMed, MRCP
      Associate Consultant, National University Cancer Institute, Singapore
    • Part 2: Experiences with Oncomine Solutions for clinical research
    • OCA Plus DNA evaluation for comprehensive genomic profiling in clinical research
      OCT 22, 2020 1:15 PM SGT
      OCA Plus DNA evaluation for comprehensive genomic profiling in clinical research
      Ahwon Lee, MD, PhD
      Professor, Catholic University of Korea and Pathologist, Seoul St. Mary's Hospital
    • Latest Developments with the Genexus System
      OCT 22, 2020 1:35 PM SGT
      Latest Developments with the Genexus System
      Dr. Jose Luis Costa
      Medical Director, Thermo Fisher Scientific
    • Part 3: Genexus Live Demo
    • LIVE DEMO: The Ion Torrent Genexus System
      OCT 22, 2020 2:10 PM SGT
      LIVE DEMO: The Ion Torrent Genexus System
      Andrew Hutchison
      Associate Director of Product Management, Clinical Sequencing Division, Thermo Fisher Scientific
  • Europe/North America Live Session 2
    • Part 1: NGS in precision oncology - general education
    • NGS for precision oncology in solid tumors: from research to clinical practice
      OCT 22, 2020 3:05 PM CEST
      NGS for precision oncology in solid tumors: from research to clinical practice
      Nicola Normanno, MD
      Director of the Cell Biology and Biotherapy Unit and Translational Research Department, National Cancer Institute Fondazione G. Pascale, Naples
    • Part 2: Experiences with Oncomine Solutions for clinical research
    • Next Generation rEvolution in Myeloid Neoplasms clinical research
      OCT 22, 2020 3:35 PM CEST
      Next Generation rEvolution in Myeloid Neoplasms clinical research
      Giada Rotunno, PhD
      Research Scientist, University of Florence
    • NGS evolution in Solid Tumours, from S5-XL to Genexus
      OCT 22, 2020 4:20 PM CEST
      NGS evolution in Solid Tumours, from S5-XL to Genexus
      Javier Hernandez-Losa, PhD
      Director of Molecular Biology Laboratory, Department of Pathology - Vall d´Hebron Hospital
    • First Experiences with Oncomine™ Comprehensive Assay Plus for comprehensive genomic profiling
      OCT 22, 2020 4:40 PM CEST
      First Experiences with Oncomine™ Comprehensive Assay Plus for comprehensive genomic profiling
      Ines Raineri, MD
      Staff Pathologist, Institute for Pathology medica AG
    • Part 3: Genexus Live Demo
    • LIVE DEMO: The Ion Torrent Genexus System
      OCT 22, 2020 5:15 PM CEST
      LIVE DEMO: The Ion Torrent Genexus System
      Andrew Hutchison
      Associate Director of Product Management, Clinical Sequencing Division, Thermo Fisher Scientific
  • North America/Australia Live Session 3
    • Part 1: NGS in precision oncology - general education
    • Molecular Testing of NSCLC Biopsies: Making mountains out of molehills
      OCT 22, 2020 12:05 PM PDT
      Molecular Testing of NSCLC Biopsies: Making mountains out of molehills
      Carmen Kletecka, MD, FCAP, FASCP
      Medical Director, Molecular Oncology Diagnostics Laboratory - U.S. Department of Veterans Affairs
    • Clinical impact of Next-Generation Sequencing (NGS) Testing: A hematopathologist's perspective
      OCT 22, 2020 12:25 PM PDT
      Clinical impact of Next-Generation Sequencing (NGS) Testing: A hematopathologist's perspective
      Megan S. Lim, MD, PhD
      Director of the Division of Hematopathology, Hospital of the University of Pennsylvania
    • Part 2: Experiences with Oncomine Solutions for clinical research
    • Utilizing the Genexus System to Detect Complex Genetic Variants in Human Tissue Specimens
      OCT 22, 2020 1:15 PM PDT
      Utilizing the Genexus System to Detect Complex Genetic Variants in Human Tissue Specimens
      Craig Mackinnon, MD, PhD
      Director, Genomic Diagnostics and Bioinformatics - Professor, Department of Pathology, University of Alabama at Birmingham
    • Evaluation of the Oncomine Comprehensive Assay Plus for Profiling of Solid Tumours
      OCT 22, 2020 1:35 PM PDT
      Evaluation of the Oncomine Comprehensive Assay Plus for Profiling of Solid Tumours
      Jane Bayani, PhD
      Principal Research Scientist, Ontario Institute for Cancer Research
    • Part 3: Genexus Live Demo
    • LIVE DEMO: The Ion Torrent Genexus System
      OCT 22, 2020 2:10 PM PDT
      LIVE DEMO: The Ion Torrent Genexus System
      Andrew Hutchison
      Associate Director of Product Management, Clinical Sequencing Division, Thermo Fisher Scientific
Speakers

  • MODERATOR: Luca Quagliata, PhD
    Global Head of Medical Affairs, Clinical NGS and Oncology Division, Thermo Fisher Scientific
  • Ilaria Alborelli, PhD
    Scientific Operations Manager, Molecular Assay Development Unit Institute of Medical Genetics and Pathology, University Hospital of Basel - Switzerland
    Biography
      Dr. Alborelli received her Master's Degree in Molecular Biology at the University of Milan in 2011 and completed her PhD in 2016 in the field of Genetics at the Biozentrum of Basel, Switzerland, where she studied signaling pathway reception using CRISPR/Cas9-based genome engineering and acute protein manipulation. She then continued this project as a post-doctoral fellow working on engineering single-chain antibodies (nanobodies) for in vivo protein manipulation. Since 2017 she joined the Institute of Medical Genetics and Pathology in Basel as scientific project manager of the Molecular Assay Development Unit, working on the development and evaluation of novel molecular diagnostics assays. Her main focus is the establishment of tools for biomarkers assessment in the field of immunotherapy and the clinical validation of molecular assays for tissue and liquid biopsy.
    • Jane Bayani, PhD
      Principal Research Scientist, Ontario Institute for Cancer Research
      Biography
        Dr. Bayani is a Principal Research Scientist at the Ontario Institute for Cancer Research in the Department of Diagnostic Development. She obtained her PhD at the University of Toronto in the Department of Laboratory Medicine and Pathobiology. She has an extensive background in molecular pathology and molecular cytogenetics and now leads a number of the genomic translational research projects as part of the senior scientific team in Diagnostic Development. Her focus is on precision medicine approaches for prognostic and predictive biomarkers in early hormone receptor positive breast cancers and in early prostate cancer.
      • Dr. Jose Luis Costa
        Medical Director, Thermo Fisher Scientific
        Biography

          José Luis Costa carried out his undergraduate studies at the University of Porto in Portugal and obtained his Ph.D. degree in Biology at Uppsala University in Sweden. Prior to joining the Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) in 2006, he carried out postdoctoral research at the Vrije University Medical Center in Amsterdam, The Netherlands. He was appointed, in 2014, as Affiliated Professor at the Medical Faculty of the University of Porto. In 2020, joined Thermo Fisher Scientific as EMEA Medical Affairs Director part of the Clinical NGS and Oncology Division. Throughout his career he seeks to promote the uptake of Precision Medicine for the benefit of patients through the application of the latest technologies in the diagnosis and the search for precision therapies.

        • Kojo Elenitoba-Johnson, MD
          Director, Center for Personalized Diagnostics Director, Division of Precision and Computational Diagnostics, University of Pennsylvania Perelman School of Medicine
          Biography
            KOJO S. J. ELENITOBA-JOHNSON, MD is the Peter C. Nowell, MD, Professor and Founding Director of the Penn Center for Personalized Diagnostics, and Founding Director of the Division of Precision and Computational Diagnostics at the Perelman School of Medicine at the University of Pennsylvania. Dr. Elenitoba-Johnson earned his medical degree from the College of Medicine, University of Lagos in Lagos, Nigeria. He has board certification in AP/CP, hematopathology and molecular genetic pathology. His research focuses on molecular pathogenesis and precision diagnostics with particular emphasis on identification of therapeutic targets for hematopoietic neoplasia. Elenitoba-Johnson has been recognized with numerous awards, including the Ramzi Cotran Young Investigator Award from the United States and Canadian Academy of Pathology in 2006 and the Outstanding Investigator Award given by the American Society for Investigative Pathology (2012). In 2018, he served as President of the Association of Molecular Pathologists (AMP). He has authored more than 170 peer-reviewed research publications and has contributed over 20 chapters in professional text-books.
          • Marianne Grantham
            Clinical Scientist, Head of Cytogenetics and Molecular Haematology, Barts Health NHS Trust The Royal London Hospital
            Biography
              Marianne Grantham is a Clinical Scientist and Head of the Cytogenetics and Molecular Haematology Department at Barts Health NHS Trust in London. After graduating from the University of Birmingham with a Bachelor's degree in Genetics in 1996, she joined the NHS to train as a Clinical Cytogeneticist. Early on in her career she discovered her passion lay in the genomics of haematological malignancies and its integration into clinical care. Marianne has worked in several large teaching hospitals across the globe including Great Ormond Street Hospital for Sick Children and St Vincent's Hospital in Sydney Australia and has worked at Barts Health since 2003. Marianne has a specialist interest in training and people development including making genomics accessible for all healthcare staff and is an honorary lecturer at Queen Mary, University of London. In 2019, Marianne was appointed as the Lead Scientist for Haematological Malignancies for the North Thames Genomic Laboratory Hub.
            • Javier Hernandez-Losa, PhD
              Director of Molecular Biology Laboratory, Department of Pathology - Vall d´Hebron Hospital
              Biography

                Dr. Hernández Losa is Director of Molecular Biology Laboratory in the Department of Pathology from the Vall d´Hebron Hospital in Barcelona. He has trained in Cancer Research, focusing on the signaling and virus detection pathways in FFPE human samples at the Department of Pathology in Hospital Puerta de Hierro (Madrid). After his Ph.D. in Biochemistry and Molecular Biology, he moved to Vall d´Hebron Hospital endorsing extensive experience in drug synergisms in different in vitro models of breast and pancreatic cancer, also in the field of biomarkers, being today one of the reference laboratories in Molecular Pathology. In addition in the last five years, the laboratory has validated by immunohistochemistry more than 12 prognostic and/or predictive markers of cancer. Thanks to these molecular analyzes based on real-time PCR and NGS have contributed to the selection of patients for the different clinical trials carried out at our institution. Dr. Hernández-Losa has been also involved in different technologies validation for mutational analysis of KRAS, NRAS, BRAF, PIK3CA, and EGFR genes in samples from colorectal cancer and NSCLC patients, as well as in exosome samples obtained from primary tumors.

              • Michael Hummel, PhD
                Head of Molecular Pathology, Charité - Universitätsmedizin Berlin, Institute of Pathology, Germany
                Biography
                  Prof. Dr Michael Hummel is head of the molecular diagnostics at the Institute of Pathology (Charité, Berlin) and a longstanding researcher with a scientific topic for molecular mechanisms in malignant lymphoma (more than 350 high ranking publications). Molecular diagnostics at Charité covers a broad spectrum of assays ranging from simple PCRs for the detection of viral and bacterial infections, complex PCRs for B- and T-cell clonality, RT-PCR based gene expression for breast cancer, FISH for chromosomal alterations and targeted NGS (started in June 2014) for mutation analysis in cancer tissues and liquid biopsies. The samples of many thousands of patients are being analyzed in our molecular lab every year. For the NGS assays, we are running the S5XL/ION Chef workflow as well as Illumina and QIAGEN platforms. Since March 2018, Charité is member of the Thermo Fisher Center of Excellence Program (COEP). In addition to the above described activities Michael Hummel is the director of the central biobank at the Charité and the Berlin Institute of Health (BIH). Furthermore he is Director of the German Biobank Node and Coordinator of the German Biobank Alliance. In this function he is responsible for the coordination and harmonization of the national biobanking activities and for the representation of the German biobank community at the European level in the frame of the biobanking infrastructure BBMRI-ERIC.
                • Andrew Hutchison
                  Associate Director of Product Management, Clinical Sequencing Division, Thermo Fisher Scientific
                • Philip Jermann, PhD
                  Director of the Molecular Assay Development Unit, Institute of Pathology and Medical Genetics of Basel
                  Biography
                    Dr. Jermann received his Master's Degree in Biochemistry at the ETH in Zurich in 2009 and did his PhD studies in the field of epigenetics at the Friedrich Miescher Institute in Basel, Switzerland, where he studied the function of histone- and DNA modifications in embryonic stem cells. He then worked as an expert for next-generation sequencing where he helped establish and support several NGS-based diagnostic laboratories throughout Switzerland and the EMEA region. In 2017, Dr. Jermann joined the Institute of Medical Genetics and Pathology in Basel where he and his team are responsible for the development and evaluation of novel molecular diagnostics assays.
                  • Carmen Kletecka, MD, FCAP, FASCP
                    Medical Director, Molecular Oncology Diagnostics Laboratory - U.S. Department of Veterans Affairs
                    Biography

                      Dr. Kletecka a board certified and fellowship trained Molecular Pathologist. She performed her residency training in anatomic and clinical pathology at Case Western Reserve University Hospitals of Cleveland and fellowship subspecialty training in Molecular Genetic Pathology and Surgical Pathology at TriCore Reference Laboratories and the University of New Mexico Hospital. She currently serves as the Medical Director of the VISN22 Molecular Diagnostics Laboratory in Los Angeles where she and her team implemented molecular oncology testing by next generation sequencing for the VA system.

                    • Ahwon Lee, MD, PhD
                      Professor, Catholic University of Korea and Pathologist, Seoul St. Mary's Hospital
                      Biography

                        Dr. Ahwon Lee is a professor of the college of medicine in the Catholic university of Korea, and a pathologist in Seoul St. Mary’s hospital who works with clinicians to find actionable mutations with various molecular biomarkers. As a pioneer of NGS routine test in Korea, she has set up and implemented comprehensive NGS tests for a solid tumor under the Korean health insurance reimbursement. She has published numbers of textbooks and scientific papers on breast pathology and gynecological oncology. Today she shares her precious experience and perspective with us about OCA Plus test.

                      • Xia Li, PhD, FACMG, DABMGG
                        Scientific Medical Director, Sonora Quest Laboratories, Tempe, US
                        Biography
                          Dr. Xia Li is the Scientific Medical Director of Genetics/Genomics Division at Sonora Quest Laboratories and Associate Professor of Pathology Department at University of Arizona. She oversees the operation of the laboratory and participates in the teaching and training of medical students and residents. Dr. Li has been working in the field of Genetics/Genomics diagnostics since 2008, and was certified in both Molecular and Cytogenetics through ABMGG. Before joining Sonora Quest Laboratories in 2016, Dr. Li was the Associate Director of Cytogenetics Laboratory at Cincinnati Children's Hospital from 2013 to 2016, and Associate Director of Cytogenetics Laboratory at AmeriPath Northeast from 2010-2013. She has extensive experience in cancer diagnostics using karyotyping, FISH, PCR, microarray and NGS technologies. She has published over 50 peer-reviewed articles and owns 2 patents. Dr. Li enjoys dancing, hiking and sewing. She has sewed over 200 cloth masks for colleagues and friends during this pandemic.
                        • Megan S. Lim, MD, PhD
                          Director of the Division of Hematopathology, Hospital of the University of Pennsylvania
                          Biography

                            Megan S. Lim, MD, PhD is the Director of the Division of Hematopathology, Hospital of the University of Pennsylvania, Director of the Hematopathology Fellowship Program, and the Director of the Lymphoma Biology Program at the Abramson Cancer Center. She is a Professor within the Department of Pathology and Laboratory Medicine, Dr. Lim received an MD from the University of Calgary and a PhD in Molecular Oncology from the University of Calgary and National Cancer Institute Lab of Pathology jointly. Dr. Lim obtained her Hematopathology fellowship training at the National Cancer Institute after which she assumed a faculty position at the University of Toronto (1998-2000), the University of Utah (2000-2006). the University of Michigan (2006-2015) before moving to the University of Pennsylvania in 2015. Dr. Lim is certified by the American Board of Pathology in Anatomic Pathology, with subspecialty certification in Hematopathology and Molecular Genetic Pathology.  She has held numerous leadership positions and served on training and education committees for the Association of Molecular Pathology and the United States Academy of Pathology. She is a member of the Board of Directors for the United States Academy of Pathology. She is the Vice-Chair of the Non-Hodgkin Lymphoma Disease Committee of the Children’s Oncology Group and participates in integrated translational research in pediatric lymphoma. Her research interests are focused on elucidating mechanisms involved in lymphoma pathogenesis which are supported by the NIH. She has participated and directed numerous CME activities for AMP, ASCP, CAP, and the USCAP.

                          • Timothy Looney, PhD
                            Associate Director, Bioinformatics; Clinical Next-Generation Sequencing
                            Biography
                              Dr. Looney is an accomplished computational biologist and immunologist with expertise in methods and applications of B and T cell receptor sequencing, including biomarker discovery and assay development. He is an Associate Director of Bioinformatics and the Informatics Lead for Immune Repertoire Sequencing within the Clinical Sequencing Division at Thermo Fisher Scientific. Dr. Looney's interest focuses on biomarker and basic immunology applications of immune repertoire analysis. He received a PhD in Genetics from the University of Chicago and performed his post-doctoral work at Stanford University, where he developed methods for immune repertoire sequencing.
                            • Siew-Kee (Amanda) Low, PhD
                              Group Leader for Cancer Neoantigen Vaccine Development Group, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research (JFCR)
                              Biography
                                2008-2011: Doctor of Philosophy (Ph.D) in Medical Genomics, The University of Tokyo, Japan. 2011-2012: JSPS Postdoctoral fellows at Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo and visiting researcher for the Division of Genetics, National Cancer Center Research Institute, Japan. 2012-2014: Research Scientist at Laboratory for Statistical Analysis, Center for Integrative Medical Sciences, The Institute of Physical and Chemical Research (RIKEN), Japan. 2015-2016: Lecturer at Faculty of Pharmacy, University of Sydney, Australia. 2017-Current: Group leader for Cancer Neoantigen Vaccine Development Group, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research (JFCR). Siew-Kee (Amanda) Low has been working extensively in genomic research that expands from cancer genomics, pharmacogenomics and various genomic studies for complex diseases. During her Ph.D. and postdoctoral fellows, she has performed comprehensive genomic analysis by utilizing large-scale genome-wide association studies (GWAS) and whole genome/exome studies to identify genetic variations associated with various complex diseases and pharmacogenomics studies. She is also the lead biostatistician representing Biobank Japan participating various international consortium. She has published in top-notch journals such as Nature Genetics, PNAS, Human Molecular genetics and etc. Currently, she is establishing the liquid biopsy system for cancer suivellance and monitoring in JFCR. As part of the Japan national project "Innovative AI hospital system", she is one of the leaders to standardize and implement liquid biopsy in the medical system in Japan.
                              • Craig Mackinnon, MD, PhD
                                Director, Genomic Diagnostics and Bioinformatics - Professor, Department of Pathology, University of Alabama at Birmingham
                                Biography

                                  Alexander “Craig” Mackinnon Jr., M.D., Ph.D., is the inaugural director of the Division of Genomics Diagnostics and Bioinformatics in the Department of Pathology, School of Medicine at the University of Alabama at Birmingham. Mackinnon is leading ongoing efforts to establish the Precision Diagnostic Laboratory at UAB. A board-certified anatomical and molecular genetic pathologist, Mackinnon joined UAB after serving as associate professor in the Department of Pathology at the Medical College of Wisconsin. Mackinnon directed the Clinical and Translational Research Laboratory (CTRL) at MCW, where he provided interpretation related to the pathology of tumor samples. The lab developed multiple Next Generation Sequencing-based panels targeting variants in both DNA and RNA. He has experience designing and validating targeted, custom DNA and RNA sequencing assays. Mackinnon’s lab interpreted a range of tests, from sequencing data to digital quantitative imaging for immunohistochemical analysis. Mackinnon is a member of the College of American Pathologists and the American Society of Clinical Pathology, where he served on the Molecular Pathology Section, Pathologist Recertification Individualized Self-Assessment Examination Committee.

                                • Natalie Ngoi, MBBS, MMed, MRCP
                                  Associate Consultant, National University Cancer Institute, Singapore
                                  Biography

                                    Dr Natalie Ngoi a medical oncologist at the National University Cancer Institute, Singapore (NCIS). Her primary clinical and research interests are in gynaecological cancers, genitourinary cancers, and precision oncology. Dr Ngoi graduated from the Yong Loo Lin School of Medicine, National University of Singapore with the degree of MBBS with Honours. She completed her Internal Medicine training at the National University Health System, Singapore and was awarded the Gordon Ransome Gold Medal in Internal Medicine. She undertook specialist training in Medical Oncology at the National University Cancer Institute, Singapore, and qualified as a Medical Oncologist in 2018. Dr Ngoi is currently an Associate Consultant in the gynaecological cancer and genitourinary cancer tumour groups at NCIS, and is an active member of the Gynecologic Cancer Group Singapore (GCGS) and Asia Pacific Gynaecologic Oncology Trials Group (APGOT). She is actively involved in the running of clinical trials at the Developmental Therapeutics Unit (NCIS), and is involved in ovarian cancer research at the Cancer Science Institute of Singapore (CSI).

                                  • Nicola Normanno, MD
                                    Director of the Cell Biology and Biotherapy Unit and Translational Research Department, National Cancer Institute Fondazione G. Pascale, Naples
                                    Biography

                                      Dr. Normanno, MD earned his Medical Doctor Degree in 1988 at the Medical School, University of Naples (Italy) Federico II. After a residency in Oncology at the Oncology Department of the same university, in 1991 he achieved the specialisation in Medical Oncology, and in 2001 in Haematology. Between 1990 and 1993, Dr Normanno did a postdoctoral fellowship at the Tumor Growth Factor Section, Laboratory of Tumour Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. After being senior Investigator and later Acting Chief (2004-2005) at the Experimental Therapy Section, INT-Fondazione Pascale, Naples, Dr Normanno is currently Director of the Cell Biology and Biotherapy-Unit at the same Hospital, and since 2006 also Director of the Translational Research Department. Since 1993 Dr Normanno's area of research has been the study of the role of growth factors and receptors of the EGF family in the pathogenesis of solid tumors; the identification of markers of response or resistance to anti-EGFR agents; the implementation of precision medicine in the path of care of cancer patients. Dr Normanno is a member of the European Society for Medical Oncology (ESMO), the American Association for Cancer Research (AACR), the Italian Association of Medical Oncology (AIOM), and the Italian Cancer Society (SIC). He is from 2018 President of the International Quality Network for Pathology (IQN Path) and from 2020 President of the Italian Cancer Society (SIC). Dr Normanno is a reviewer for several peer-reviewed journals including Annals of Oncology, Clinical Cancer Research, International Journal of Cancer, European Journal of Cancer, British Journal of Cancer, Nature Communications. He is also Editor of Exploration of Targeted Anti-tumor Therapy and Associate Editor of BMC Cancer and Gene. Dr Normanno is the author of over 200 papers published in peer-reviewed journals with an H Index of 68.

                                    • Ines Raineri, MD
                                      Staff Pathologist, Institute for Pathology medica AG
                                      Biography

                                        After receiving her MD degree from the University of Zurich, Switzerland, Ines Raineri attended a postgraduate course for basic science at the same university. She then worked as postdoctoral fellow at the Institute for Medical Microbiology of the University of Basel, Switzerland, investigating HIV-promoter-insertions in the human genome. She received fellowships from the Swiss National Foundation, Ciba-Geigy Jubiläumsstiftung, Roche Research Foundation and Holderbank Stiftung to work as postdoctoral fellow at the University of California San Francisco, where she was later hired to work as research assistant geneticist. During her nearly 8 years at UCSF she was involved in generating transgenic cell lines and mice to study oxygen free radical metabolism. After returning to Switzerland, she worked again at the Institute for Medical Microbiology of the University of Basel, establishing knockdown systems to rapidly evaluate gene functions in embryonic stem cells. She then moved on to train as a board-certified pathologist and currently works as a staff pathologist at the Institute for Pathology medica AG in Zurich in molecular pathology, histology and cytology.

                                      • Pathmanathan Rajadurai, MBBS, FRCPA, FRCPath
                                        Senior Consultant Pathologist and Laboratory Director
                                        Biography
                                          Dr. Pathmanathan is Senior Consultant Pathologist and Laboratory Director in the Subang Jaya by Medical Centre, Subang Jaya. He is also currently Professor of Anatomical Pathology in the Tan Sri Jeffrey Cheah School of Medicine, Monash University, Adjunct Professor of Pathology in Manipal University (Manipal campus) and is Visting Professor of Pathology in the University of Malaya Medical Centre. He is an established researcher with more than 230 scientific publications in international and peer-reviewed journals and serves on the Editorial Board of "Pathology". He serves as advisor and consultant for multinational pathology diagnostics companies as well as pharmaceutical companies. His current research areas are in the molecular pathology of cancers, telepathology and digital imaging.
                                        • Giada Rotunno, PhD
                                          Research Scientist, University of Florence
                                          Biography

                                            Giada Rotunno is a biotechnologist, currently researcher scientist at the University of Florence, Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM) directed by Professor AM Vannucchi. Dr. Rotunno graduated in Medical and Pharmaceutical Biotechnology in 2012 and obtained her PhD degree in Biomedical science in Experimental and Clinical Oncology at the University of Florence in 2015. Her main scientific interests concern hematological disorders with particular focus on myeloproliferative neoplasms (MPN). She is working since 2012 on the study of mutation complexity of chronic and acute myeloid neoplasms, contributing to the refinement of the risk stratification of patients with MPN. In these years, she developed the Next Generation Sequencing (NGS) techniques actually used at CRIMM center. Dr Rotunno published 45 papers on high-impact factor journals including Blood, Leukemia and other peer-reviewed journals on myeloid neoplasms.

                                          • Aaron Tan, PhD
                                            Oncology Fellow, Resident Physician, National Cancer Centre, Singapore
                                            Biography

                                              Aaron is currently an Oncology Fellow at the National Cancer Centre Singapore (NCCS), having completed his specialty training in Medical Oncology in Sydney, Australia. He also completed a PhD in cancer drug discovery at The University of Sydney. His current focus is in early phase clinical trials and lung cancer translational research. As an early career researcher, he has received numerous awards and achievements including an International Association for the Study of Lung Cancer (IASLC) Fellowship 2018-2020, ASCO 2018 and ESMO Asia 2019 Merit Awards.

                                            C.E. Credits

                                            The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


                                            Help

                                            General LabRoots Questions

                                            email support@labroots.com  

                                            Virtual Events and Webinars

                                            Supported Configurations

                                            • Operating System Internet Explorer Firefox Chrome Safari
                                              Vista IE8+ FF10+ Chrome15+
                                              Windows 7 IE8+ FF10+ Chrome15+
                                              Windows 8 IE10 FF10+ Chrome15+
                                              Mac OS X   FF10+ Chrome15+ Safari5.1+
                                            • Cookie settings: session cookies enabled
                                            • Browser configuration must have JavaScript enabled
                                            • Adobe Flash player 10.2 or later

                                            To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                            Internet Connection

                                            • A minimum of 100Kbps is recommended for audio-only events
                                            • A minimum of 300Kbps is recommended for speaker on-video events

                                            Computer Equipment

                                            • Screen Resolution: Minimum 1024x768
                                            • Video Card: 65,000 colors minimum
                                            • Sound card and speakers (or headphones) for hearing webcast in full format
                                            • Audio Card: 16-bit minimum
                                            • RAM: 512MB of free RAM

                                            Firewall Protocol

                                            • HTTP on port 80 or HTTPS on port 443
                                            • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                            • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                            Work-At-Home Attendees

                                            • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                            For A Seamless Experience

                                            When using a mobile device, FREE Mobile Apps are available:

                                            - For viewing Webinars:

                                            - For viewing Virtual Events

                                            Attendee Guide

                                            • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                            Virtual Event and Webinar Support:

                                            Continuing Education (CME/CE) Support

                                            Demographics

                                            Specialty

                                            Cancer

                                            Molecular Genetics

                                            Molecular Diagnostics

                                            Molecular Biology

                                            Cancer Research

                                            Personalized Medicine

                                            Research And Development

                                            Genetics

                                            Gene

                                            Cancer Diagnostics

                                            Research

                                            Genomics

                                            Oncology

                                            Human Genetics

                                            Disease

                                            Geography

                                            North America30%

                                            Asia29%

                                            Europe28%

                                            South America4%

                                            Africa4%

                                            Oceania3%

                                            Registration Source

                                            Website Visitors86%

                                            Email Promotions6%

                                            LabRoots Registration (Also interested in)4%

                                            Website Banners2%

                                            Social Media Promotions1%

                                            WAVE Newsletter Promotion1%

                                            Client/Sponsor Promotions1%

                                            Job Title

                                            Executive11%

                                            Facility/Department Manager11%

                                            Research Scientist10%

                                            Student9%

                                            Educator/Faculty8%

                                            Medical Doctor/Specialist7%

                                            Scientist7%

                                            Marketing/Sales6%

                                            Lab Management6%

                                            Medical Laboratory Technician5%

                                            Biologist5%

                                            Clinical Laboratory Scientist4%

                                            Pathologist4%

                                            Post Doc3%

                                            Consultant3%

                                            Genetic Counselor1%

                                            Organization

                                            Academic Institution21%

                                            Hospital15%

                                            Biotech Company11%

                                            Clinical Laboratory8%

                                            Life Science Company7%

                                            Research Institute4%

                                            Government3%

                                            Distribution/sales3%

                                            Diagnostic Company3%

                                            Pharmaceutical Company3%

                                            Consultant2%

                                            Medical Center2%

                                            Medical School2%

                                            Government/public2%

                                            Other5%

                                            Show Resources
                                            Attendees
                                            • See more